Cue Biopharma Welcomes New Chief Development Officer
BOSTON, Mass. — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company focused on creating innovative therapeutic biologics, recently made a significant move by appointing Dr. Daniel Baker as the interim chief development officer. This appointment is notable for the positive impact it may have on the company’s future direction in developing treatments for cancer and autoimmune diseases.
Inducement Award to Dr. Baker
As a gesture of commitment, the company granted Dr. Baker an inducement option award, which was officially approved by the independent directors of Cue Biopharma. This award includes the option to purchase 200,000 shares of the company’s common stock at an exercise price of $1.06 per share. The exercise price corresponds to the closing stock price on the Nasdaq Capital Market on the date of the grant.
Vesting Schedule of the Inducement Award
Dr. Baker’s inducement award will vest over a period of two years. The vesting occurs in four equal installments, starting six months after the grant date. This structure ensures that as long as Dr. Baker remains with the company through each vesting milestone, he will gain access to these stock options.
About Cue Biopharma
Cue Biopharma is pioneering a new frontier in biologics, dedicated to developing therapies that specifically target T cells within the patient’s immune system. Utilizing their proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), they significantly modulate targeted T cells to enhance the body’s immune response while minimizing side effects typically associated with broader immune modulation.
With operational headquarters based in Boston, Massachusetts, Cue Biopharma is fueled by a management team and board with extensive expertise in immunology and the clinical development of protein biologics. This strong leadership foundation positions Cue Biopharma at the forefront of immunology advancements.
Recent Developments and Future Direction
The appointment of Dr. Baker aligns with Cue Biopharma’s strategic vision to enhance their operational efficiency and development capabilities. By bringing in a leader with substantial experience in drug development and a passion for innovation, the company is well poised to advance its clinical programs that focus on autoimmune diseases and oncology.
Commitment to Innovation
Cue Biopharma's commitment to creating targeted therapies embodies a transformative approach in the biopharmaceutical industry. The focus remains on precision in treatment, ensuring that therapies harness the full potential of the immune system while limiting unwanted effects, a significant concern in traditional treatments.
Looking ahead, the company aims to expand its pipeline of treatments, fostering partnerships and collaborations that can enhance research outcomes and accelerate the path to innovative solutions for patients.
Investor and Media Contact
Cue Biopharma encourages inquiries from interested investors and media to learn more about their pioneering work in the biopharmaceutical field. For investor inquiries, Marie Campinell, Senior Director of Corporate Communications, is available. Additionally, Jonathan Pappas from LifeSci Communications can assist media contacts.
Frequently Asked Questions
What is the main focus of Cue Biopharma?
Cue Biopharma focuses on developing a novel class of therapeutic biologics that engage and modulate disease-specific T cells for cancer and autoimmune disease treatment.
Who has been appointed as the new interim chief development officer?
Daniel Baker, M.D., has been appointed as the new interim chief development officer at Cue Biopharma.
What is the significance of the inducement option award?
The inducement option award is a commitment from Cue Biopharma that compensates Dr. Baker for his expertise and aligns his interests with the company's success.
How does the inducement option award vest?
The inducement award vests over two years in four equal installments, contingent on Dr. Baker’s continued employment with the company.
How can one contact Cue Biopharma for more information?
Inquiries can be directed to Marie Campinell for investor relations or Jonathan Pappas for media questions.
